In collaboration with

and

Acknowledgement of Commercial Support
This activity is supported by an educational grant from Takeda Pharmaceuticals U.S.A., Inc

Title: Multidisciplinary Collaboration and Education: Learning to Recognize and Manage the Patient with AATD-LD

Release | Expiration: TBD (will update with the actual date of launch)

Statement of Need:
Alpha-1 antitrypsin deficiency-associated liver disease (AATD-LD) remains significantly underdiagnosed due to a critical lack of clinician awareness, especially among allergists/immunologists, pulmonologists, gastroenterologists, and primary care providers, who often overlook AATD as a primary liver condition, particularly in the absence of prominent pulmonary symptoms. Diagnostic delays, which can span years and worsen clinical status, stem from the underutilization of guideline-recommended screening and non-invasive liver assessment tools, and a limited understanding of the diverse and variable natural history of AATD-LD across different genotypes (PiZZ, PiMZ, PiSZ). This educational deficit results in inconsistent application of comprehensive diagnostic pathways and inadequate long-term monitoring for severe hepatic consequences like cirrhosis and hepatocellular carcinoma (HCC).

Furthermore, a significant professional practice gap exists in the management of AATD-LD, which currently lacks approved disease-modifying pharmacological treatments beyond supportive care and transplantation. Clinicians often fail to appreciate that established augmentation therapy for lung disease does not impact the progression of liver damage. Therefore, there is an urgent need for multi-specialty education to improve competence in applying liver-specific monitoring strategies and evaluating the rapidly emerging landscape of liver-targeted therapeutic strategies, such as RNA interference and gene editing approaches. This program is designed to bridge these gaps, ensuring that all providers involved in the care of AATD patients can improve timely diagnosis, risk stratification, and patient counseling, ultimately leading to better outcomes.

Educational Objectives:

1. UTILIZE comprehensive diagnostic pathways, incorporating serum AAT testing, genetic confirmation, and appropriate non-invasive liver assessments, for the early and accurate diagnosis of AATD-associated liver disease in at-risk individuals.
2. DIFFERENTIATE the varied clinical presentations and potential long-term hepatic consequences of AATD across different patient populations and genotypes, including risk factors for disease progression and development of hepatocellular carcinoma.
3. EVALUATE the mechanisms of action, potential efficacy, and safety profiles of emerging therapeutic strategies for the management of AATD-associated liver disease.

Target Audience:
Allergists, Immunologists, Pulmonologists, Hepatologists, Gastroenterologists, Primary Care clinicians (physicians and APPs)

Faculty:

Technical Writer:
Brittane Strahan, MSN, RN, CCRP

Disclosures
No relevant financial disclosures

Reviewer
Mary Beth Fasano, MD, MSPH FAAAAI
Professor Emerita Medicine and Pediatrics
University of Iowa Carver College of Medicine

Disclosures
No relevant financial disclosures

Accredited Provider Disclosure:
None of the planners, reviewers, and AAAAI, American Liver Foundation and RealCME staff for this educational activity have relevant financial relationship(s) with ineligible companies to disclose.

Disclosure of Financial Relationships Policy:
AAAAI adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CME/CE activity, including faculty, planners, reviewers, or others are required to disclose all financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Accredited Provider & Accreditation Statements:
This activity is accredited through AAAAI. 

CME: The American Academy of Allergy Asthma and Immunology (AAAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CE: The American Academy of Allergy Asthma and Immunology (AAAAI) is a Provider approved by the California Board of Registered Nursing, Provider #10704.

Credit Designation Statement:
The AAAAI designates this activity for up to 4.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Unlabeled Use:
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a clinician relative to diagnostic and treatment options for a specific patient's medical condition.

Disclaimer:
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of AAAAI, American Liver Foundation and RealCME. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

If you have any questions relating to the accreditation of this activity, please contact cme@aaaai.org

Method of Participation/Instructions:
Please proceed with the activity until you have successfully completed this program, answered all test questions, completed the post-assessment and evaluation, and have received a digital copy of your credit certificate.

In order to claim the maximum amount of credit available, you must complete all of the following:

• Baseline/Final Assessments: 30 minutes each for a total of up to 1.00 hour of CME
• Three (3) Self-Study Modules: 15 minutes each for a total of up to 0.75 hour of CME
• Two (2) Live Group Discussion: 45 minutes each for a total of up to 1.50 hour of CME
• Two (2) Group Challenges: 30 minutes each for a total of up to 1.00 hour of CME
• Action Plan (1) development: 30 minutes for a total of 0.50 hour of CME 

Privacy Statement:
The American Academy of Allergy, Asthma & Immunology (AAAAI) takes your privacy seriously. AAAAI will only use your personal information to administer your registration, attendance, and credit claiming/attendance record for this activity, to provide services that you have requested from AAAAI and otherwise as you may expressly consent. A complete copy of AAAAI’s Legal and Privacy Notices, the terms of which are incorporated herein, can be found here.

By providing consent, you are allowing AAAAI to process your personal data. AAAAI will collect and store information you provide in the Registration Forms for the purposes of enabling us to register your attendance at the activity; to assist with administrative, planning and marketing purposes; and to allow the compilation and analysis of statistics relevant to AAAAI. 
 
The information you provide in the Registration Forms, and information provided at any other time during this activity, including without limitation any feedback obtained during the activity, will be used by AAAAI to offer, provide and continue to improve its educational activities and other services. The AAAAI may also use your email address to communicate important information regarding this activity and for marketing purposes for future activities. AAAAI will not otherwise, without your consent, use or disclose your personal information for any purpose unless it would reasonably be expected that such a purpose is related to the offer, provision and improvement of the activity or where such purpose is permitted or required by law. 

I understand that it is my right to withhold consent to the above Privacy and Data Protection Notice, or to withdraw my previous consent at any time. I further understand that without my consent, it is not possible to process my registration/housing request for this activity. Please contact the AAAAI Education Team at (414) 272-6071 if you have any further questions about how this will affect your registration request for this activity.